Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Treatment of the hemophilias. Curr Opin Hematol 1995 Sep;2(5):386-94

Date

09/01/1995

Pubmed ID

9372024

DOI

10.1097/00062752-199502050-00010

Scopus ID

2-s2.0-0029361553 (requires institutional sign-in at Scopus site)   2 Citations

Abstract

The treatment of hemophilia and conditions that frequently afflict hemophilic patients, such as arthropathy, HIV infection, and viral hepatitis, are discussed. Long-term prophylaxis with Factor VIII or IX is very successful at preventing disabling arthropathy. Much research is being done on gene therapy and prolonged periods of Factor VIII and IX expression have already been achieved in animals. In HIV-seropositive hemophilic patients the CD4 count appears to decline more slowly in patients treated with higher purity than with lower-purity products. Thermoresistant non-lipid-enveloped viruses, such as parvovirus, do not become inactivated by the currently used virucidal methods.

Author List

Moll S, White GC 2nd

Author

Gilbert C. White MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Blood Coagulation Factors
Creutzfeldt-Jakob Syndrome
Genetic Therapy
Hemophilia A
Hemorrhage
Hepatitis, Viral, Human
Humans
Transfusion Reaction
Virus Diseases